Trial Profile
A phase I study Afatinib in Combination of Osimertinib in patients with Relapsed Non-Small Cell Lung Cancer after failure of prior Osimertinib
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer
- 01 Mar 2021 Status changed from not yet recruiting to completed.